Temozolomide Chronotherapy in Glioma: A Systematic Review
Outcomes for patients with high-grade glioma remain poor. Temozolomide (TMZ) is the only drug approved for first-line treatment of glioblastoma multiforme, the most aggressive form of glioma. Chronotherapy highlights the potential benefit of timed TMZ administration. This is based on pre-clinical st...
| Published in: | Current Oncology |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/2/147 |